Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.
Profitability
This table compares Mereo BioPharma Group and TScan Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mereo BioPharma Group | N/A | -74.82% | -64.28% |
| TScan Therapeutics | -1,655.35% | -108.72% | -54.47% |
Insider and Institutional Ownership
62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 6.2% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mereo BioPharma Group | $500,000.00 | 88.79 | -$41.88 million | ($0.04) | -6.95 |
| TScan Therapeutics | $10.32 million | 2.10 | -$129.77 million | ($0.91) | -0.35 |
Mereo BioPharma Group has higher earnings, but lower revenue than TScan Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Mereo BioPharma Group has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Mereo BioPharma Group and TScan Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mereo BioPharma Group | 2 | 3 | 3 | 0 | 2.12 |
| TScan Therapeutics | 1 | 5 | 2 | 0 | 2.12 |
Mereo BioPharma Group currently has a consensus price target of $1.67, suggesting a potential upside of 499.52%. TScan Therapeutics has a consensus price target of $2.67, suggesting a potential upside of 735.95%. Given TScan Therapeutics’ higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Mereo BioPharma Group.
Summary
Mereo BioPharma Group beats TScan Therapeutics on 7 of the 13 factors compared between the two stocks.
About Mereo BioPharma Group
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.
